SDR16C6 inhibitors are chemical compounds that interact with the short-chain dehydrogenase/reductase family member 16C6 (SDR16C6), a specific enzyme categorized within the large superfamily of short-chain dehydrogenase/reductases (SDRs). SDR16C6, like other members of the SDR family, plays a pivotal role in various metabolic processes involving the reduction or oxidation of small molecules, including steroids, retinoids, and lipid substrates. Inhibitors of SDR16C6 disrupt its enzymatic activity, impeding the enzyme's ability to catalyze the redox reactions integral to these metabolic pathways. This inhibition can result from direct binding of the inhibitor to the enzyme's active site or via allosteric modulation, where binding occurs at a different site that leads to conformational changes. The specificity of these inhibitors for SDR16C6 can vary, and this specificity is often dictated by the inhibitor's molecular structure, which aligns with the unique binding domains of the enzyme.
At a molecular level, SDR16C6 inhibitors exhibit a diverse range of structural features, often including hydrophobic and polar regions that interact with critical residues in the enzyme's active or regulatory sites. These inhibitors may mimic natural substrates of SDR16C6, acting as competitive inhibitors, or they may induce non-competitive inhibition through interactions that alter the enzyme's conformation without directly competing with substrate molecules. The nature of inhibition-whether reversible or irreversible-depends on the chemical structure of the inhibitor and the type of bond formation involved. Characterization of these inhibitors involves a combination of techniques, including enzymatic assays, crystallographic studies, and computational modeling to understand the enzyme-inhibitor complex and the underlying binding dynamics. SDR16C6 inhibitors thus represent a fascinating area of study in enzyme kinetics and metabolic regulation due to their ability to precisely modulate enzyme activity at a molecular level.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Metformin | 657-24-9 | sc-507370 | 10 mg | $79.00 | 2 | |
May influence metabolic pathways, potentially affecting SDR16C6-related processes. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $257.00 $505.00 | 9 | |
Specifically inhibits HMG-CoA reductase, used to lower cholesterol levels. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Activates peroxisome proliferator-activated receptor alpha (PPARα), influencing lipid metabolism. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $53.00 $89.00 | 7 | |
Inhibits acetaldehyde dehydrogenase, affecting alcohol metabolism. | ||||||
Epalrestat | 82159-09-9 | sc-218319 | 10 mg | $200.00 | 2 | |
Specifically inhibits aldose reductase, studied in the research of diabetic complications. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
A thiazolidinedione that activates PPARγ, used in diabetes management. | ||||||
Nicotinamide riboside | 1341-23-7 | sc-507345 | 10 mg | $411.00 | ||
A precursor of NAD+, potentially supporting dehydrogenase/reductase activity. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
An AMPK activator, used to study metabolic processes. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
A sirtuin activator, potentially influencing dehydrogenase/reductase activity. | ||||||